Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients
Information source: AHS Cancer Control Alberta
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cancer; Pain
Intervention: Sublingual Methadone (Drug)
Phase: Phase 2
Status: Terminated
Sponsored by: Alberta Health Services Official(s) and/or principal investigator(s): Neil Hagen, MD, Principal Investigator, Affiliation: AHS Cancer Control Alberta
Summary
The purpose of this Phase II study is to determine the feasibility of the dose titration and
assessment protocol in the outpatient population before conducting an appropriately powered
phase III study. Thus the primary purpose of this study is to determine the proportion of
patients who are successfully titrated to an optimal dose of sublingual (Under the tongue)
methadone and then studied at that optimal dose with successive episodes of breakthrough
pain.
Clinical Details
Official title: Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients: a Phase II Multicenter, Open Label, Feasibility Study
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: to demonstrate the feasibility of a novel model to assess sublingual methadone to breakthrough pain in the outpatient setting
Secondary outcome: to develop a model of PK/PD study of breakthrough painto develop a research tool, the Breakthrough Pain Assessment Tool (BPAT) to demonstrate proof of concept
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Pain due to cancer or its treatment; controlled baseline pain;
- episodes of breakthrough pain every day that are "4/10" in severity or greater, ;
- ast 10 minutes or longer, and
- are responsive to short acting oral opioids such as morphine or hydromorphone;
- are able to hole a volume of 1. 0cc of water under the tongue for a 5-minute period;
are able to provide written informed consent;
- are able to fill out the study forms
Exclusion Criteria:
- Severe underlying respiratory disease such that an investigator is wary about the
risk of respiratory failure from modest doses of opioid;
- prior sensitivity to methadone;
- currently are being administered methadone;
- have breakthrough pain that in the opinion of the investigator is likely to change
within the next seven days (recent or imminent radiation therapy to the main site of
pain,
- new chemotherapy or use of an injectable bisphosphonate likely to alter the pain, new
use corticosteroids within the past week with a corresponding change in pain, or
other interventions judged likely to alter pain);
- are clinically unstable or have a life expectancy of less than one month making
completion of the trial unlikely
Locations and Contacts
Tom Baker Cancer Center, Calgary, Alberta T2N 4N2, Canada
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Additional Information
Starting date: July 2008
Last updated: January 24, 2013
|